Close Menu

HPV

Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.

The test detects the presence of two biomarkers within a single cell associated with HPV infections that can progress to cervical cancer.

The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.

The firm's investigational immunotherapy PRGN-2009 will be evaluated in patients as a monotherapy and in combination with an investigational bifunctional fusion protein.

The agency granted accelerated approval based on the vaccine's ability to prevent HPV-related anogenital disease, but a 6,000-patient study will assess its ability to prevent oral cancer.

PRGN-2009 showed anti-tumor activity in preclinical studies and now will be evaluated in humans as a monotherapy and in combination with a bifunctional fusion protein.

Researchers are making improvements to viral-DNA detection methods and are exploring applications not just for screening but also disease monitoring.

The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.